,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-04-21 05:15:00,"When Peter Gassner launched Veeva Systems ( VEEV ) in 2007, he didn't expect to outstrip $500 million in revenue, watch its stock triple in a span of less than three years or expand its arsenal of products to 23 applications.",0.6401438117027283,0.013391663320362568,0.3464645445346832,positive,0.6267521381378174
1,2017-04-21 05:15:00,"Instead, Gassner was in ""survival mode.""",0.18312810361385345,0.03651365637779236,0.7803582549095154,neutral,0.1466144472360611
2,2017-04-21 05:15:00,"""In the beginning you have nothing - you have no products, no customers, no people, nothing,"" said Gassner, a one-time alum of Salesforce.com ( CRM ).",0.02644925005733967,0.17362800240516663,0.7999228239059448,neutral,-0.1471787542104721
3,2017-04-21 05:15:00,"""You have exactly zero.",0.09283702075481415,0.09836739301681519,0.8087956309318542,neutral,-0.005530372262001038
4,2017-04-21 05:15:00,"So, then you have to start hiring some people, you have to make a product and get your first customer.""",0.229390487074852,0.022404473274946213,0.7482050061225891,neutral,0.20698601007461548
5,2017-04-21 05:15:00,"He added: ""Grand plans are sort of interesting, but it doesn't mean anything until you can hire your first developer or get your first customer.""",0.1233523041009903,0.013805591501295567,0.8628421425819397,neutral,0.1095467135310173
6,2017-04-21 05:15:00,"Today, Veeva provides the cloud backbone for the $1.7 trillion life sciences industry where it rivals the likes of Medidata Solutions ( MDSO ), and counts companies like Pfizer ( PFE ), Novartis ( NVS ), Amgen (AMGN) and Eli Lilly (LLY ) among its customers.",0.45235463976860046,0.008644559420645237,0.5390007495880127,neutral,0.4437100887298584
7,2017-04-21 05:15:00,"As drugmakers tackle the challenge of developing, testing and manufacturing lifesaving drugs, Veeva operates the cloud system in the background.",0.029545070603489876,0.010292592458426952,0.960162341594696,neutral,0.019252479076385498
8,2017-04-21 05:15:00,Its dual roles include organizing doctor information for pharmaceutical reps and clinical trial data/graphs for companies.,0.0178024023771286,0.006414275616407394,0.9757832884788513,neutral,0.011388126760721207
9,2017-04-21 05:15:00,"Gassner calls the latter point ""Veeva's second act.""",0.06274627149105072,0.09140180796384811,0.8458519577980042,neutral,-0.028655536472797394
10,2017-04-21 05:15:00,"In total, Veeva estimates its total addressable market at $7 billion, though Gassner expects its nascent third act could add another $1 billion onto that.",0.183212548494339,0.008080057799816132,0.8087074160575867,neutral,0.17513248324394226
11,2017-04-21 05:15:00,"After all, becoming bigger and better is exactly what companies like Alphabet (GOOGL), IBM (IBM) and Cisco Systems (CSCO) did, he said.",0.48020806908607483,0.01093349140137434,0.5088584423065186,neutral,0.4692745804786682
12,2017-04-21 05:15:00,"""The important thing in a company is, if you want to keep it going, your second act should probably end up being as big or bigger than your first act,"" he told Investor's Business Daily.",0.3315572142601013,0.02039705216884613,0.6480457186698914,neutral,0.311160147190094
13,2017-04-21 05:15:00,"""A company that can make its second act bigger than its first act has some long-term ability to reinvent itself.""",0.8047507405281067,0.018282782286405563,0.17696653306484222,positive,0.786467969417572
14,2017-04-21 05:15:00,Veeva launched 10 years ago with a single application to help pharmaceutical reps organize drug data to make stronger doctor pitches.,0.18109746277332306,0.007488032802939415,0.8114145398139954,neutral,0.1736094355583191
15,2017-04-21 05:15:00,"Today, 60% of the globe's pharma sales reps use what's called Veeva CRM - customer relationship management - an iPad application.",0.025327404960989952,0.010168449953198433,0.9645041227340698,neutral,0.01515895500779152
16,2017-04-21 05:15:00,"Getting drug company managers to buy in early on wasn't difficult, Gassner says.",0.19565069675445557,0.020958514884114265,0.7833907604217529,neutral,0.17469218373298645
17,2017-04-21 05:15:00,"IBD'S TAKE:Veeva Systems stock has an IBD Composite Rating of 98 out of a best-possible 99, meaning it outperforms 97% of all stocks in terms of key growth metrics.",0.9179574251174927,0.02129388600587845,0.06074870377779007,positive,0.8966635465621948
18,2017-04-21 05:15:00,Head to IBD Stock Checkup for a list of strong software leaders.,0.14172255992889404,0.011603930033743382,0.8466735482215881,neutral,0.13011862337589264
19,2017-04-21 05:15:00,"""I think the life sciences industry is more business-outcome oriented,"" he said.",0.11664148420095444,0.008667451329529285,0.8746910095214844,neutral,0.10797403007745743
20,2017-04-21 05:15:00,"""There's important things the CEOs focus on: 'Can I get my drug approved?",0.05722149834036827,0.014150143601000309,0.9286283254623413,neutral,0.043071355670690536
21,2017-04-21 05:15:00,Can I get it to market effectively before the patent expires?',0.3534814417362213,0.02810503914952278,0.618413507938385,neutral,0.32537639141082764
22,2017-04-21 05:15:00,"If there's a tool, cloud or not cloud, that can help them, that's generally what they want.""",0.3970155417919159,0.02317745052278042,0.5798070430755615,neutral,0.3738380968570709
23,2017-04-21 05:15:00,"Fast forward to 2017, Veeva CRM is part of the company's Commercial Cloud business.",0.04361870884895325,0.0044676330871880054,0.9519137144088745,neutral,0.03915107622742653
24,2017-04-21 05:15:00,"Commercial Cloud grew in fiscal 2017 on major CRM wins and amid expansions at top 20 pharmaceutical firms, Veeva said in its earnings news release.",0.9495320916175842,0.015130475163459778,0.03533744812011719,positive,0.9344016313552856
25,2017-04-21 05:15:00,"The business accounts for two-thirds of Veeva's sales, Gassner estimates.",0.02213135175406933,0.0076320297084748745,0.9702366590499878,neutral,0.014499321579933167
26,2017-04-21 05:15:00,"But it's Veeva's second act that really has Wall Street keyed up, he said.",0.2842063009738922,0.05089324340224266,0.6649004817008972,neutral,0.23331305384635925
27,2017-04-21 05:15:00,"Veeva Vault was launched in 2011 with a single customer and the goal of organizing all content involved in clinical trials - documents, videos, images and data records.",0.04373851791024208,0.004495945759117603,0.9517654776573181,neutral,0.03924257308244705
28,2017-04-21 05:15:00,"Vault represents about a third of Veeva's total sales and targets a $4 billion total-addressable market, Gassner said.",0.06879867613315582,0.0045818304643034935,0.9266194701194763,neutral,0.06421684473752975
29,2017-04-21 05:15:00,He sees Vault as the reason for recent excitement around Veeva stock.,0.2276691198348999,0.06688611954450607,0.7054448127746582,neutral,0.16078299283981323
30,2017-04-21 05:15:00,"Shares are up 29% since January and, on March 13, burst out of a cup-with-handle formation that began in November, topping a 45.95 buy point on a deeper Salesforce partnership.",0.9412217736244202,0.02521486021578312,0.03356334939599037,positive,0.9160069227218628
31,2017-04-21 05:15:00,The stock is now more than 14% extended from that point.,0.07991591095924377,0.014602775685489178,0.9054813385009766,neutral,0.06531313806772232
32,2017-04-21 05:15:00,"From a bottom of 17.11 in May 2014 - seven months after Veeva's IPO - to an all-time intraday high of 53.37 reached Friday, shares gained nearly 212%.",0.9453531503677368,0.02944265492260456,0.025204163044691086,positive,0.9159104824066162
33,2017-04-21 05:15:00,"Shares ultimately retreated by Friday's close, but were up again Monday, gaining 1.4% to close at 52.55.",0.7022739052772522,0.2578431963920593,0.039882905781269073,positive,0.44443070888519287
34,2017-04-21 05:15:00,"[ibdchart symbol=""VEEV"" type=""weekly"" size=""threequarter"" position=""rightchart"" ]In 2011, Vault brought in under $10 million in sales, Gassner said.",0.21180252730846405,0.011917895637452602,0.776279628276825,neutral,0.19988463819026947
35,2017-04-21 05:15:00,"Today, Vault's annualized run rate is north of $220 million.",0.15030984580516815,0.007840601727366447,0.8418495059013367,neutral,0.14246924221515656
36,2017-04-21 05:15:00,"As a whole, Veeva is aiming to top a $1 billion annualized run rate in 2020, and Veeva is already tracking ahead of that, says Cornelio Ash, analyst at William O'Neil & Co., an affiliate of Investor's Business Daily.",0.8079255819320679,0.013196741230785847,0.17887772619724274,positive,0.7947288155555725
37,2017-04-21 05:15:00,"Now, Vault is prepping for a potential third act by looking for opportunities outside life sciences - a first for Veeva.",0.5607891082763672,0.011886808089911938,0.4273240864276886,positive,0.5489022731781006
38,2017-04-21 05:15:00,Gassner says Veeva could see an additional $1 billion opportunity in taking Vault to other manufacturing-heavy industries like chemicals and consumer packaging.,0.5077435374259949,0.009339967742562294,0.4829164445400238,positive,0.4984035789966583
39,2017-04-21 05:15:00,"O'Neil's Ash says success in that venture will be a ""game-changer"" for Veeva.",0.9052053093910217,0.015138430520892143,0.07965623587369919,positive,0.8900668621063232
40,2017-04-21 05:15:00,"""What that would be saying is they've got a lockdown on the steps,"" he told IBD.",0.05613236129283905,0.5728442072868347,0.3710234463214874,negative,-0.5167118310928345
41,2017-04-21 05:15:00,"""Then it just becomes, what door do they want to knock down?",0.031335629522800446,0.07278097420930862,0.8958834409713745,neutral,-0.04144534468650818
42,2017-04-21 05:15:00,The potential is there.,0.29065442085266113,0.01049917284399271,0.6988463997840881,neutral,0.2801552414894104
43,2017-04-21 05:15:00,"That's probably why (Veeva stock) continues to trade at a premium.""",0.43246278166770935,0.05266961827874184,0.5148676037788391,neutral,0.3797931671142578
44,2017-04-21 05:15:00,Gassner says Veeva will gain traction outside life sciences using the same method it employed in 2007 and 2011 when it launched its major Commercial Cloud and Vault divisions.,0.8102521896362305,0.010343929752707481,0.1794038712978363,positive,0.7999082803726196
45,2017-04-21 05:15:00,"Inside the company it's called ""the Veeva way.""",0.04843773692846298,0.011232209391891956,0.9403300285339355,neutral,0.0372055284678936
46,2017-04-21 05:15:00,"The method worked in life sciences, after all.",0.08757016062736511,0.015483113005757332,0.8969467282295227,neutral,0.07208704948425293
47,2017-04-21 05:15:00,Veeva has an estimated 50%-60% of the CRM market.,0.03401130437850952,0.004826499614864588,0.9611621499061584,neutral,0.02918480522930622
48,2017-04-21 05:15:00,"And though its sales in clinical trials and regulatory processes match Medidata's, that's 100% of Medidata's sales vs. a small - and growing - chunk of Veeva's.",0.2224012166261673,0.04917803779244423,0.7284207940101624,neutral,0.17322318255901337
49,2017-04-21 05:15:00,"""Your brand becomes what you're good at,"" Gassner said.",0.5446175932884216,0.011241494677960873,0.44414085149765015,positive,0.5333760976791382
50,2017-04-21 05:15:00,"""If we become good at delivering this value outside life sciences, then I think over time we'll become known for that.""",0.8756541013717651,0.016177311539649963,0.1081685796380043,positive,0.8594768047332764
51,2017-04-21 05:15:00,"To that end, Veeva is part of a collaboration that includes AstraZeneca (AZN), Allergan (AGN), Biogen (BIIB), Lilly, Novartis, GlaxoSmithKline (GSK), Pfizer and others called Align Biopharma.",0.2074728161096573,0.005928269121795893,0.7865989208221436,neutral,0.20154455304145813
52,2017-04-21 05:15:00,Align is aiming to iron out the technological standards for the life sciences world.,0.152409628033638,0.005578951444476843,0.8420114517211914,neutral,0.14683067798614502
53,2017-04-21 05:15:00,"Veeva could do the same in a sector outside of the life sciences, Ash said.",0.2665877342224121,0.007665453478693962,0.725746750831604,neutral,0.258922278881073
54,2017-04-21 05:15:00,"""That's literally getting feedback from the horse's mouth of how they should develop the platform,"" he said.",0.2005966752767563,0.011352418921887875,0.7880508899688721,neutral,0.18924425542354584
55,2017-04-21 05:15:00,"""To me, to be successful outside that, they're going to need that same kind of feedback in other sectors.""",0.7541627287864685,0.016013123095035553,0.22982409596443176,positive,0.7381495833396912
56,2017-04-21 05:15:00,"Veeva Helps The Medicine Go Down For Drug Giants

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.01321061048656702,0.01677936501801014,0.9700100421905518,neutral,-0.003568754531443119
